Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results

FDA's Cardiovascular and Renal Drugs Advisory Committee votes 7-1 in favor of ticagrelor's approval for acute coronary syndromes despite rejecting AstraZeneca's aspirin-dosing theory as the sole cause of lack of benefit in the U.S. population.